PMID- 33381643 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231110 IS - 2578-5125 (Print) IS - 2378-8763 (Electronic) IS - 2378-8763 (Linking) VI - 5 IP - 4 DP - 2020 TI - Cannabinoids in the Management of Acute Pain: A Systematic Review and Meta-analysis. PG - 290-297 LID - 10.1089/can.2019.0079 [doi] AB - Objective: To synthesize the best evidence surrounding the efficacy of cannabinoids for acute pain in the clinical setting based on subjective pain scores and observed adverse effects. Design: Systematic review with meta-analysis. Data Sources: PubMed, Embase, Cochrane Databases, and Google Scholar. Eligibility Criteria: English-language randomized-controlled clinical trials comparing cannabinoids with placebo in patients with acute pain. Data Extraction and Synthesis: Study quality was assessed using the Cochrane risk of bias tool. All stages were conducted independently by a team of three reviewers. Data were pooled through meta-analysis and stratified by route of administration. Primary Outcomes and Measures: Patient-reported pain and adverse events (AEs). Results: Six trials (678 participants) were included examining oral (5 trials) and intramuscular (1 trial) cannabinoids. Overall, there was a small but statistically significant treatment effect favoring the use of cannabinoids over placebo (-0.90, 95% confidence interval [CI] -1.69 to -0.1, i (2)=65%, p=0.03). When stratified by route of administration, intramuscular cannabinoids were found to have a significant reduction in pain relative to placebo (-2.98, 95% CI -4.09 to -1.87, i (2)=0%, p<0.0001). No difference in effect was observed between oral cannabinoids and placebo (-0.21, 95% CI -0.64 to 0.22, i (2)=3%, p=0.34). Serious AEs were rare, and similar across the cannabinoid (14/374, 3.7%) and placebo groups (8/304, 2.6%). Conclusions: There is low-quality evidence indicating that cannabinoids may be a safe alternative for a small but significant reduction in subjective pain score when treating acute pain, with intramuscular administration resulting in a greater reduction relative to oral. Higher quality, long-term randomized-controlled trials examining whether there may be a role for cannabinoids in treating acute pain are required. CI - Copyright 2020, Mary Ann Liebert, Inc., publishers. FAU - Gazendam, Aaron AU - Gazendam A AD - Center for Evidence-Based Orthopaedics, Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Canada. FAU - Nucci, Nicholas AU - Nucci N AD - Northern Ontario School of Medicine, Lakehead University, Thunder Bay, Canada. FAU - Gouveia, Kyle AU - Gouveia K AD - Michael G. DeGroote School of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Canada. FAU - Abdel Khalik, Hassaan AU - Abdel Khalik H AD - Michael G. DeGroote School of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Canada. FAU - Rubinger, Luc AU - Rubinger L AD - Center for Evidence-Based Orthopaedics, Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Canada. FAU - Johal, Herman AU - Johal H AD - Center for Evidence-Based Orthopaedics, Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Canada. AD - Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada. LA - eng PT - Journal Article PT - Review DEP - 20201215 PL - United States TA - Cannabis Cannabinoid Res JT - Cannabis and cannabinoid research JID - 101684827 PMC - PMC7759255 OTO - NOTNLM OT - acute pain OT - cannabinoids OT - meta-analysis OT - surgical pain OT - systematic review COIS- No competing financial interests exist. EDAT- 2021/01/01 06:00 MHDA- 2021/01/01 06:01 PMCR- 2021/12/15 CRDT- 2020/12/31 05:27 PHST- 2020/12/31 05:27 [entrez] PHST- 2021/01/01 06:00 [pubmed] PHST- 2021/01/01 06:01 [medline] PHST- 2021/12/15 00:00 [pmc-release] AID - 10.1089/can.2019.0079 [pii] AID - 10.1089/can.2019.0079 [doi] PST - epublish SO - Cannabis Cannabinoid Res. 2020 Dec 15;5(4):290-297. doi: 10.1089/can.2019.0079. eCollection 2020.